Affiliation: University of Washington
- Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis CChihiro Morishima
Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA
Am J Gastroenterol 107:1388-98. 2012..We investigated whether reduced hepatic inflammation was associated with clinical benefit in 834 patients with a baseline and follow-up biopsy 1.5 years after randomization to peginterferon or observation...
- Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis CC Morishima
Division of Virology, Department of Laboratory Medicine, University of Washington, Seattle, WA 98109, USA
J Viral Hepat 19:404-13. 2012..009). Poorer CD4+ T cell proliferative function was associated with more advanced liver disease in chronic hepatitis C and may be further affected by long-term PEG-IFN treatment...
- Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killingChihiro Morishima
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
Hepatology 43:573-80. 2006..035). In conclusion, NK cell cytolytic function does not appear to be impaired in chronic hepatitis C, but higher levels of NK cell cytolysis are associated with less liver fibrosis...
- HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trialChihiro Morishima
Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
Hepatology 44:360-7. 2006..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
- Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis CChihiro Morishima
Department of Laboratory Medicine and Pediatrics, University of Washington, Seattle, USA
J Infect Dis 193:931-40. 2006..Thus, in patients with advanced hepatic fibrosis due to HCV infection, pretreatment HCV-specific immune responses and increased QS variability appear to hinder viral clearance by pegylated IFN- alpha 2a and ribavirin combination therapy...
- Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infectionChihiro Morishima
Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
Gastroenterology 138:671-81, 681.e1-2. 2010..The goal of this study was to determine whether silymarin has in vitro effects on immune function that might have implications for its potential effect on hepatitis C virus (HCV)-induced liver disease...
- Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfectionChihiro Morishima
Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
J Infect Dis 196:577-86. 2007..Human immunodeficiency virus (HIV) coinfection and low peripheral blood CD4(+) T cell counts are associated with increased hepatitis C liver disease...
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CChihiro Morishima
Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
Hepatology 48:1412-9. 2008..With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001)...
- Identification of hepatoprotective flavonolignans from silymarinStephen J Polyak
Department of Laboratory Medicine, Microbiology and Global Health, University of Washington, Seattle, WA 98104, USA
Proc Natl Acad Sci U S A 107:5995-9. 2010..The data suggest that silymarin- and silymarin-derived compounds may influence HCV disease course in some patients. Studies where standardized silymarin is dosed to identify specific clinical endpoints are urgently needed...
- Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized SilymarinStephen J Polyak
Department of Laboratory Medicine, University of Washington, Seattle, Washington 98104 2499, USA
Gastroenterology 132:1925-36. 2007..Milk thistle's clinical benefits for chronic hepatitis C are unsettled due to variability in standardization of the herbal product...
- Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysisStephen J Polyak
Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
Virol J 2:41. 2005..QS diversity and complexity were quantified using heteroduplex mobility assays (HMA)...
- Hepatitis C virus-specific cytolytic T cell responses after antiviral therapyChihiro Morishima
University of Washington, School of Medicine, Seattle, WA 98195, USA
Clin Immunol 108:211-20. 2003....
- High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infectionChia C Wang
Department of Medicine, University of Washington, Seattle 98104 2499, USA
J Infect Dis 193:672-6. 2006..This association was also observed in 1 subject with acute HCV infection. Thus, our data demonstrate that salivary HCV RNA detection was associated with serum HCV RNA load in individuals who were chronically or acutely infected with HCV...
- Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trialZachary D Goodman
Armed Forces Institute of Pathology, Division of Hepatic Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA
Hepatology 50:1738-49. 2009..Maintenance therapy with low-dose peginterferon had no effect on fibrosis changes in any of the groups...
- Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammationJessica Wagoner
Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
PLoS ONE 6:e16464. 2011..These data underscore the differences and similarities between the intravenous and oral formulations of silibinin, which could influence the clinical effects of this mixture on patients with chronic liver diseases...
- Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemiaMark H Wener
Department of Laboratory Medicine, University of Washington, Seattle 98195, USA
Arthritis Rheum 50:2305-8. 2004..To determine if antibodies to cyclic citrullinated peptide (anti-CCP) are found in chronic hepatitis C virus (HCV) infection...
- Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapyH Nina Kim
Department of Medicine, University of Washington, Seattle, Washington 98104, USA
AIDS Patient Care STDS 21:718-23. 2007..These observations suggest that flares of hepatitis C in the setting of the immune reconstitution inflammatory syndrome can occur even in those patients who have undetectable serum HCV levels prior to HAART initiation...
- Strengths and limitations of commercial tests for hepatitis C virus RNA quantificationChihiro Morishima
Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
J Clin Microbiol 42:421-5. 2004..Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay...
- Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infectionLei Yu
1Division of Gastroenterology, University of Washington, Seattle, WA 98195 6175, USA
Br J Nutr 115:193-201. 2016..Future studies should assess whether reducing cholesterol intake, among women who consume an excessive amount, can decrease HCV-related mortality. ..
- Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation studyKelly G Paulson
Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington
Cancer . 2016..Antibodies to MCPyV oncoprotein (T-antigens) have been correlated with MCC tumor burden. The present study assesses the clinical utility of MCPyV-oncoprotein antibody titers for MCC prognostication and surveillance...
- Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trialLei Yu
Division of Gastroenterology, University of Washington, Seattle, Washington Electronic address
Clin Gastroenterol Hepatol 11:1661-6.e1-3. 2013..Little is known about whether dietary cholesterol affects disease progression in patients with chronic hepatitis C virus infection...
- Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot studyKaren F Murray
Hepatobiliary Program, Division of Gastroenterology and Nutrition, Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
Pediatrics 111:153-7. 2003..The purpose of this study was to determine the prevalence of HCV and high-risk behaviors in a population of incarcerated youths...
- Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
Gastroenterology 126:1015-23; discussion 947. 2004..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee
Control Clin Trials 25:472-92. 2004..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
- Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis CAlan Lee Rothman
Center for Infectious Disease and Vaccine Research and Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Hepatology 41:617-25. 2005....
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohortAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
Hepatology 42:282-92. 2005..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
- Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky
Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
Gastroenterology 131:1440-51. 2006....
- Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson
Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
Hepatology 44:1675-84. 2006..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
- Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trialAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 5:245-54. 2007....
- Antiviral effects of silymarin against hepatitis C: the jury is still outStephen J Polyak
Hepatology 48:345-6. 2008
- Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis CKaren L Lindsay
Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
Clin Gastroenterol Hepatol 6:234-41. 2008..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
- Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severityApril Bingham
From Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland 20892 1301, USA
Medicine (Baltimore) 87:70-86. 2008..Further study is warranted to investigate the pathogenesis of acquired LD in patients with DM...
- T Cell Immunity & Liver Fibrosis in HCV/HIV CoinfectionChihiro Morishima; Fiscal Year: 2003..Finally, we will test the hypotheses that HCV/HIV coinfected subjects treated with HAART will demonstrate improved HCV-specific CD4+ T cell function that is not fibrogenic, and is sequestered to the liver. ..